Desmoid tumor in the male breast refractory to systemic treatment: case report
DOI:
https://doi.org/10.29289/2594539420240024%20Palavras-chave:
breast, male, desmoid fibromatosis, diagnostic imaging, MRIResumo
Desmoid-type fibromatosis, an intermediate soft tissue tumor known for its local infiltrative behavior and high recurrence rate, is uncommon in the male breast. The report outlines the clinical journey of a 44-year-old male presenting with a rapidly growing breast mass, initially managed with a watchful waiting approach and subsequent systemic therapies including celecoxib, sorafenib, and a combination of methotrexate and vinblastine, all of which proved ineffective. Genetic testing revealed a catenin beta 1 (CTNNB1) mutation, indicative of a sporadic tumor. Despite various treatment attempts, significant tumor progression was observed, necessitating surgical intervention followed by radiotherapy. This case underscores the challenges in managing desmoid tumors, emphasizing the importance of multidisciplinary approaches and the potential need for surgical resection when conventional therapies fail.
Downloads
Referências
1. Ha KY, Deleon P, Hamilton R. Breast fibromatosis mimicking
breast carcinoma. Proc (Bayl Univ Med Cent). 2013;26(1):22-4.
https://doi.org/10.1080/08998280.2013.11928903
2. Devouassoux-Shisheboran M, Schammel MD, Man YG,
Tavassoli FA. Fibromatosis of the breast: age-correlated
morphofunctional features of 33 cases. Arch Pathol Lab Med.
2000;124(2):276-80. https://doi.org/10.5858/2000-124-0276-
FOTB
3. Zhang Z, Shi J, Yang T, Liu T, Zhang K. Management of
aggressive fibromatosis. Oncol Lett. 2021;21(1):43. https://doi.
org/10.3892/ol.2020.12304
4. Crombé A, Kind M, Ray-Coquard I, Isambert N, Chevreau C,
André T, et al. Progressive desmoid tumor: radiomics compared
with conventional response criteria for predicting progression
during systemic therapy – a multicenter study by the French
Sarcoma Group. AJR Am J Roentgenol. 2020;215(6):1539-48.
https://doi.org/10.2214/AJR.19.22635
5. Rosen PP, Ernsberger D. Mammary fibromatosis. A benign
spindle-cell tumor with significant risk for local recurrence.
Cancer. 1989;63(7):1363-9. https://doi.org/10.1002/1097-
0142(19890401)63:7≤1363::aid-cncr2820630722≥3.0.co;2-b
6. Seo YN, Park YM, Yoon HK, Lee SJ, Choo HJ, Ryu JH. Breast
fibromatosis associated with breast implants. Jpn J Radiol.
2015;33(9):591-7. https://doi.org/10.1007/s11604-015-0461-y
REFERENCES
7. Cawson RA. Soft tissue tumors, 3rd edition, 1995. Eur J Cancer
B Oral Oncol. 1995;31(6):405. https://doi.org/ 10.1016/0964-
1955(95)90006-3
8. Ng WH, Lee JSY, Poh WT, Wong CY. Desmoid tumor
(fibromatosis) of the breast. A clinician’s dilemma--a case
report and review. Arch Surg. 1997;132(4):444-6. https://doi.
org/10.1001/archsurg.1997.01430280118021
9. Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G,
Limprecht R, et al. Imatinib induces sustained progression
arrest in RECIST progressive desmoid tumours: final
results of a phase II study of the German Interdisciplinary
Sarcoma Group (GISG). Eur J Cancer. 2017;76:60-7. https://doi.
org/10.1016/j.ejca.2017.02.001
10. Zheng C, Fang J, Wang Y, Zhou Y, Tu C, Min L. Efficacy and
safety of apatinib for patients with advanced extremity desmoid
fibromatosis: a retrospective study. J Cancer Res Clin Oncol.
2021;147(7):2127-35. https://doi.org/10.1007/s00432-020-03498-y
11. Anter AH, Abdel-Latif RM. Clinical outcome of tamoxifen
and sulindac for desmoid tumors in adults: a phase II single
institution experience. Middle East J Cancer. 2019;10(2):125-31.
12. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G.
High-dose tamoxifen and sulindac as first-line treatment
for desmoid tumors. Cancer. 2004;100(3):612-20. https://doi.
org/10.1002/cncr.11937
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 Celia Luiza de Lima Rodrigues, Soraia Quaranta Damião, Cândida Maria Alves Soares, Bianca Miranda Lago, Juliana Alves de Souza, Luciana Graziano, Camila Souza Guatelli, Almir Galvão Vieira Bitencourt
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
